Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-03-21
1997-04-01
Nazario-Gonzalez, Porfirio
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514475, 514530, 514531, 548954, 548967, 548968, 549 90, 554 13, 554214, 560124, A01N 4302
Patent
active
056166079
ABSTRACT:
Compounds of the general structure ##STR1## are disclosed, wherein X is O, C.sub.n, NH, or S, wherein n is 1, 2, 3 or 4; R1 is OH, CH.sub.3, CH.sub.2 OH, N.sub.3 or CH.sub.2 N.sub.3 ; R3 is H or CH.sub.3 ; R5 is Y-R2, wherein Y is a six-carbon chain optionally containing up to three double or triple bonds or a mixture of double and triple bonds up to a maximum of three; R2 is C.sub.1 -C.sub.10 alkyl OH, C.sub.1 -C.sub.10 alkyl N.sub.3 or COOR4, wherein R4 is H, a branched or unbranched C.sub.1 -C.sub.10 alkyl (including substituted alkyl radicals), cycloalkyl, preferably C.sub.5 or C.sub.6 cycloalkyl, or a five- or six-membered aryl radical (including substituted aryl radicals), i.e. R2 is COOH or an ester of R4; R6 is a seven-carbon chain optionally containing up to three double or triple bonds or a mixture of double and triple bonds up to a maximum of three; and . . . . . . indicates a single, double or triple bond. The compounds are analogs of hepoxilins and are used to modulate hepoxilin activity, for example in the control of inflammation or other processes mediated by intracellular calcium levels.
REFERENCES:
patent: 3775432 (1973-11-01), Siddall et al.
Lapitskaya et al., "A Chemoselective Synthesis of Functionalized 1,4-Alkadiynes (Skipped Diacetylenes)", Synthesis, pp. 65-66, Jan. 1993.
Demin et al., Chem. Abstracts 113: 402.51x, 1990.
Pace-Asciak, Chem. Abstracts 105: 58399q, 1986.
Corey et al., Tetrahed. Lett. 24:(95) "Total Synthesis of 12-(S)-10-hydroxy-trans-11, 12-epoxyeicosa-5,9,14-(Z)-trienoic acids, Metabolites of areachidonic acid in mammalian blood Plateletes", 4913-4916, 1983.
Sun Lumin et al., Tetrahed. Lett. "Palladium Mediated Allylic Mitsunobu Displacement: Stereocontrolled Sythesis of Hepoxilin A.sub.3 Trioxilin, A.sub.3 Methyl Esters" 33(16) 2091-2094, 1992.
Demin et al., Chem. Abstracts 114: 42306g, 1991.
Demin et al., Tetrahed. Lett. 34(27), "Synthesis of Racemic 11,12-cyclopropyl analogs-of Hepoxilins A.sub.3 and B.sub.3 ", 4305-4308, 1993.
Shimizu and Wolfe, "Arachidronic Acid Cascade and Signal Transduction" J. Neurochem 55:1-15, 1990.
Pace-Asciak and Nigam, "Hepoxilins modulate second messenger systems in the Human Neutrophil,"Cell-Cell Interactions in the Release of Inflammatory Mediators, 133-134, 1991.
Pace-Asciak et al., "A glutathione conjugate of hepoxilin A.sub.3 : Formation and action in the rat central nervous system", Proc. Natl. Acad. Sci. USA 87:3037-3041, 1990.
Demin Peter M.
Pace-Asciak Cecil R.
HSC Research and Development Limited Partnership
Jones Dwayne C.
Nazario-Gonzalez Porfirio
LandOfFree
Hepoxilin analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hepoxilin analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepoxilin analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-539394